Previous 10 | Next 10 |
Medpace Holdings is a healthy business trading at a discount to its intrinsic value. Price target $193-200. The company has zero debt vs peer group average of $5.6B debt. Lower risk of permanent loss of capital vs peers. Medpace top-line in the past four years grew at 17.5% CAGR v...
A late-day surge allowed the major U.S. equity averages to finish Thursday's trading with mild gains, reversing losses seen earlier in the day. The higher finish ended a two-day slide that included consecutive days of more than 2% declines from the Nasdaq. The health care sector helped buoy t...
Health-care stocks are dominating the S&P 500 on Thursday led by life sciences companies and biotech firms as investors turn to safety amid market volatility. Thermo Fisher Scientific (NYSE:TMO), Danaher (NYSE:DHR), Charles River Laboratories (CRL), Bio-Rad Laboratories (NYSE:RAD), Modern...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2021 Corporate Citizenship Report . The 2021 report demonstrates Charles River’s priorities and commitments across its key Environmental, Social and Governance (ESG) areas of foc...
Charles River Laboratories (NYSE:CRL) acquired San Diego, California-based Explora BioLabs, provider of contract vivarium research services, for ~$295M in cash. The transaction is not expected to have a material impact on Charles River’s 2022 GAAP or non-GAAP EPS, a...
– Expands Charles River Accelerator and Development Lab (CRADL™) Footprint Providing Clients with Full-Service, Turnkey Research Space – – Adds More Than 15 Vivarium Facilities Across Three Key U.S. Biohubs – – Continued Expans...
Ariel Investments’ 13F portfolio value increased from $10.94B to $11.86B this quarter. They increased Nielsen Holdings and Core Laboratories while reducing KKR and dropping Johnson & Johnson. The top three positions are Madison Square Garden Entertainment, Mattel, and F...
Charles River Laboratories International (NYSE:CRL) has appointed Flavia H. Pease as its next CFO, succeeding David R. Smith. David previously announced on January 11 that he intends to retire. Ms. Pease will join the company as Corporate Executive Vice President, effective April 25...
Chief Financial Officer Transition Plan Originally Announced on January 11 th Ms. Pease Will Join Charles River as Corporate Executive Vice President on April 25 th Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it wil...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...